Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

GlobalData's deals database analysis shows that Latham & Watkins secured the top spot by deal value, advising on transactions worth $19.4bn.